510(k) device
reSET-O
Pear Therapeutics, Inc. · Computerized Behavioral Therapy Device For Substance Use Disorders (PWE, Class II) · First FDA decision Dec 10, 2018, newest Dec 10, 2018OCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
4
Naming "reSET-O"
MAUDE reports
0
Brand "reSET-O", since 2015
PubMed studies
29
Mentioning "reSET-O"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing reSET-O
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
- Fluidized Therapy Dry Heat for Certain Musculoskeletal DisordersNational determinationOn the books150.8Updated Apr 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "reSET-O", any status and sponsor, newest update first.
- reSET-O RCT (Randomized Controlled Trial)Pivotal-lookingCompleted
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT04129580 · 100 participants · Start Sep 15, 2020 · Primary completion Jul 14, 2023
Device: reSET-O app · For: Opioid-use Disorder
Sites: Harrisburg, Pennsylvania
Johns Hopkins UniversityAcademic, hospital or other
NCT04817267 · 8 participants · Start Mar 11, 2022 · Primary completion Jan 1, 2023
Device: reSET-O app · For: Opioid-use Disorder
Sites: Baltimore, Maryland
Pear Therapeutics, Inc.Not on our public-company list
NCT05412966 · 7 participants · Start Nov 4, 2022 · Primary completion Nov 23, 2022
Device: PEAR-002B; reSET-O · For: Opioid Use Disorder
Sites: Berlin, New Jersey
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "reSET-O", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PWE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "reSET-O"[tiab]. The summary above synthesizes these.
- When Software Becomes Medicine: Ignoring It May Soon Be Malpractice.
Lakhan SE · Cureus · 2025Editorial
- Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
Maricich YA, Xiong X, Gerwien R, et al. · Curr Med Res Opin · 2021Observational Study, Research Support, Non-U.S. Gov't
- Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic.
Velez FF, Anastassopoulos KP, Colman S, et al. · Adv Ther · 2022Research Support, Non-U.S. Gov't
- Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder.
Velez FF, Huang D, Mody L, et al. · Expert Rev Pharmacoecon Outcomes Res · 2022
- Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial).
Glass JE, Dorsey CN, Beatty T, et al. · Implement Sci · 2023Clinical Trial Protocol, Research Support, N.I.H., Extramural
- A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.
Luderer H, Enman N, Gerwien R, et al. · JMIR Res Protoc · 2023
- Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial.
Luderer H, Chiodo L, Wilson A, et al. · JMIR Res Protoc · 2022
- Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder.
Velez FF, Malone DC · J Mark Access Health Policy · 2021
- The Composite Digital Therapeutic Index (cDTI): A Multidimensional Framework and Proof-of-Concept Application to FDA-Authorized Treatments.
Lakhan SE · Cureus · 2025
- Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.
Maricich YA, Bickel WK, Marsch LA, et al. · Curr Med Res Opin · 2021Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic.
Velez FF, Ruetsch C, Maricich Y · Expert Rev Pharmacoecon Outcomes Res · 2021Editorial
- Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder.
Wang W, Gellings Lowe N, Jalali A, et al. · J Med Econ · 2021
Other devices of this type
Also filed under product code PWE.
- reSetPear Therapeutics, Inc. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.